Product Code: GVR-4-68040-363-0
Transradial Access Devices Market Trends
The global transradial access devices market size was estimated at USD 2.1 billion in 2023 and is projected to grow at a CAGR of 7.8% from 2024 to 2030. The market is driven by several key factors such as the increasing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, and growing demand for minimally invasive surgeries. Furthermore, the increasing adoption of transradial access techniques by healthcare providers is expected to contribute significantly to the growth of the market.
The rising incidence of cardiovascular diseases globally is a significant driver for the market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, with an estimated 17.9 million deaths annually. In 2021, around 695,000 people died from heart disease in the U.S. that equates to one in every 5 deaths according to U.S. Centers for Disease Control and Prevention (CDC). This high prevalence of cardiovascular conditions necessitates the use of advanced medical devices such as transradial access devices for effective diagnosis and treatment.
Advancements in interventional cardiology procedures lead to the development of innovative transradial access devices that offer improved safety, efficacy, and patient outcomes. For instance, the introduction of hydrophilic coatings on sheaths reduces friction during radial artery cannulation, enhancing procedural success rates. Technological advancements result in a lower rate of access site complications and improved patient comfort during transradial interventions.
The shift towards minimally invasive procedures across various medical specialties is fueling the demand. Patients prefer minimally invasive surgeries due to shorter hospital stays, faster recovery times, and reduced risk of complications compared to traditional open surgeries. This trend positively impacts the adoption of transradial access techniques and devices in clinical practice. For instance, in September 2023, MicroVention, a neurovascular company and a subsidiary of Terumo Corporation, announced that its Sofia EX 5-F, 115-cm intracranial support catheter has received FDA 510(k) clearance for use with both transradial and transfemoral access methods. This expanded clearance enables healthcare providers to utilize the Sofia EX 5-F catheter in a wider range of procedures, providing them with greater flexibility and versatility when treating patients.
Global Transradial Access Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global transradial access devices market report based on product, end-use, application, and region.
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Catheters
- Guidewires
- Sheath & Sheat Introducers
- Accessories
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Clinics & Ambulatory Care Centers
- Others
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Drug Administration
- Fluid and Nutrition Administration
- Blood Transfusion
- Diagnostics and Testing
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
U.S.
Canada
Mexico
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
China
Japan
India
South Korea
Australia
Thailand
Brazil
Argentina
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product
- 1.2.2. End Use
- 1.2.3. Application
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Transradial Access Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of cardiovascular diseases,
- 3.2.1.2. Technological advancements
- 3.2.1.3. Growing demand for minimally invasive surgeries
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory hurdles
- 3.2.2.2. High cost of devices
- 3.2.3. Market opportunity analysis
- 3.2.3.1. Growing adoption in emerging markets
- 3.3. Transradial Access Devices Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Transradial Access Devices Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Transradial Access Devices Market Product Movement Analysis
- 4.3. Global Transradial Access Devices Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Catheters
- 4.4.1. Catheters market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5. Guidewires
- 4.5.1. Guidewires market estimates and forecasts 2018 to 2030, (USD Million)
- 4.6. Sheath and sheath introducers
- 4.6.1. Sheath and sheath introducers market estimates and forecasts 2018 to 2030, (USD Million)
- 4.7. Accessories
- 4.7.1. Accessories market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 5. Transradial Access Devices Market: End Use Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Transradial Access Devices Market End Use Movement Analysis
- 5.3. Global Transradial Access Devices Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 5.4. Hospital
- 5.4.1. Hospital market estimates and forecasts 2018 to 2030, (USD Million)
- 5.5. Clinics & Ambulatory Surgery Centers
- 5.5.1. Clinics & ambulatory surgery centers market estimates and forecasts 2018 to 2030, (USD Million)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 6. Transradial Access Devices Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Transradial Access Devices Market Application Movement Analysis
- 6.3. Global Transradial Access Devices Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 6.4. Drug Administration
- 6.4.1. Drug administration market estimates and forecasts 2018 to 2030, (USD Million)
- 6.5. Fluid and Nutrition Administration
- 6.5.1. Fluid and nutrition administration market estimates and forecasts 2018 to 2030, (USD Million)
- 6.6. Blood Transfusion
- 6.6.1. Blood transfusion market estimates and forecasts 2018 to 2030, (USD Million)
- 6.7. Diagnostics and Testing
- 6.7.1. Diagnostics and Testing market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 7. Transradial Access Devices Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Competitive scenario
- 7.6.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Competitive scenario
- 7.6.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2023
- 8.4. Company Profiles/Listing
- 8.4.1. TERUMO CORPORATION
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Medtronic
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Boston Scientific Corporation
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. BD
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Cordis
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. AngioDynamics
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Merit Medical Systems
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Edwards Lifesciences Corporation
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. NIPRO MEDICAL CORPORATION
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Abbott
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.11. Teleflex Incorporated
- 8.4.11.1. Company overview
- 8.4.11.2. Financial performance
- 8.4.11.3. Product benchmarking
- 8.4.11.4. Strategic initiatives
- 8.4.12. Surmodics, Inc.
- 8.4.12.1. Company overview
- 8.4.12.2. Financial performance
- 8.4.12.3. Product benchmarking
- 8.4.12.4. Strategic initiatives